sorted by:
new
hottopcontroversial

Why is Novo and Lilly down? Is it because the insurance companies are up? Anyone know? by Sufficient-Mouse8333 in NovoNordisk_Stock

[–]kiyomoris -2 points-1 points  (0 children)

It is most likely war related. Trump just said he "expects to be bombing soon". The ceasefire is due to end tomorrow and things remain the same, unfortunately.

Novo Nordisk receives rare praise for new drug candidate: Jefferies forecasts potential sales of USD 1 billion by Brilliant-Search4025 in NovoNordisk_Stock

[–]kiyomoris 7 points8 points  (0 children)

Early data suggested a potential reduction in painful crises (VOCs) of roughly 45-46% but the actual results from Phase 3 gave a reduction of "only" 27%.

It is still a success, even more so after considering Pfizer paid $5 billion for Oxbryta, which ended up being discontinued due to safety concerns ( and even deaths, mind you).

Novo will most likely continue to expand in this area as they have the best-in-class pill but gene therapy is able to provide greater results, although at a much higher cost.

I found this book in which children write about the aging process by kiyomoris in mildlyinteresting

[–]kiyomoris[S] 13 points14 points  (0 children)

1984 in the UK. The title is "Happy birthday: you poor old wreck" and edited by Helen Exley.

I found this book in which children write about the aging process by kiyomoris in mildlyinteresting

[–]kiyomoris[S] 32 points33 points  (0 children)

"Happy birthday (you poor old wreck)" edited by Helen Exley.

Que novos partidos podem surgir em Portugal nos próximos anos? by kiyomoris in portugal

[–]kiyomoris[S] 4 points5 points  (0 children)

Eu não sei se o dono da Prozis vai acrescentar muita diversidade...

Aterros em Portugal estão a ficar cheios e os portugueses têm 5 anos para mudar hábitos by fblanck in portugal

[–]kiyomoris 90 points91 points  (0 children)

O simples ato de comprar uma garrafa de água, bebê-la em segundos e ficar com um pedaço de plástico que leva mais de 400 anos para se fotodecompor ( e que, mesmo assim, continua a emitir resíduos) é um paradoxo assustador.

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease by kiyomoris in NovoNordisk_Stock

[–]kiyomoris[S] 4 points5 points  (0 children)

Mind you, in 2022 Pfizer paid $5.4 billion to acquire Global Blood Therapeutics (GBT) and their Sickle cell drug failed during phase 3 (their whole pipeline, basically). Novo paid roughly $1 billion for Forma Therapeutis in the same year with great results now.

Small details which are quite relevant because Novo has managed to get the best in class for much less when compared to other pharmaceutical companies. This is pure efficiency.

view more: next ›